These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22901567)

  • 21. Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.
    Singh AK; Guion P; Susil RC; Citrin DE; Ning H; Miller RW; Ullman K; Smith S; Crouse NS; Godette DJ; Stall BR; Coleman CN; Camphausen K; Ménard C
    Radiat Oncol; 2006 Aug; 1():28. PubMed ID: 16914054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup.
    Koutrouvelis PG; Lailas N; Katz S; Sehn J; Gil-Montero G; Khawand N
    J Urol; 2003 Apr; 169(4):1331-6. PubMed ID: 12629354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
    Morris WJ; Pickles T; Keyes M
    Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
    Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
    Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.
    D'Alimonte L; Helou J; Sherman C; Loblaw A; Chung HT; Ravi A; Deabreu A; Zhang L; Morton G
    Brachytherapy; 2015; 14(3):309-14. PubMed ID: 25466361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate brachytherapy: treatment strategies.
    Stone NN; Stock RG
    J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer.
    Graff P; Portalez D; Lusque A; Brun T; Aziza R; Khalifa J; Roumiguié M; Quintyn Ranty ML; Filleron T; Bachaud JM; Malavaud B
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):903-911. PubMed ID: 29510957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
    Morris LM; Izard MA; Wan WY
    Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focal salvage low-dose-rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique.
    Yamada Y; Okihara K; Masui K; Ueno A; Shiraishi T; Nakamura Y; Saito Y; Fujihara A; Hongo F; Yamada K; Ukimura O
    Int J Urol; 2020 Feb; 27(2):149-155. PubMed ID: 31721315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.
    Yamada Y; Masui K; Iwata T; Naitoh Y; Yamada K; Miki T; Okihara K
    Brachytherapy; 2015; 14(2):118-23. PubMed ID: 25304650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of local failure following prostate brachytherapy.
    Stone NN; Stock RG; White I; Unger P
    J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.
    Gómez-Iturriaga Piña A; Crook J; Borg J; Ma C
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):422-7. PubMed ID: 20832665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
    Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
    Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
    Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.
    Kestin LL; Vicini FA; Ziaja EL; Stromberg JS; Frazier RC; Martinez AA
    Cancer; 1999 Oct; 86(8):1557-66. PubMed ID: 10526285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.